ClinicalTrials.gg
RecruitingNCT06673329Updated May 13, 2026

Brodalumab in the Treatment of Immune-Related Adverse Events

A Phase 1 interventional study of Brodalumab and CT scan in Breast Cancer, Esophageal Cancer and Kidney Cancer, sponsored by Brian Henick, MD. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Brian Henick, MD · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.

Read the detailed description

The proposed study will evaluate the safety and efficacy of brodalumab in improving and resolving Immune-Related Adverse Events (irAEs) in patients treated with brodalumab. Eligible subjects must have an immune-related adverse event with the intent to treat it with steroids. Subjects will receive subcutaneous brodalumab for 24 weeks. Peripheral blood will be collected at all in-person study visits for mechanistic studies. Participants will be evaluated at week 0, 1, 2, 4, and then every 4 weeks after that until week 24 as dictated by the standard of care using a combination of telemedicine and face-to-face evaluations. Additional safety follow-up visits will occur at weeks 28 and 36. All patients will have the Columbia Suicide Severity Rating Scale (C-SSRS), and Patient Health Questionnaire-9 (PHQ-9) administered at all visits. The treatment protocol consists of subcutaneous brodalumab 210 mg administered at baseline and then at weeks 0, 1, and 2, then bi-weekly for a total of 24 weeks (the current FDA-approved dosing for plaque psoriasis). Glucocorticoids may be used at baseline at the discretion of the investigators, with the goal of tapering off of steroids over 4-8 weeks if tolerated (see proposed taper in appendix). Continued treatment beyond the 24-week course can be evaluated by the treating investigator and the Sponsor-Investigator, weighing risks versus clinical benefit.

02

Conditions studied

  • Breast Cancer
  • Esophageal Cancer
  • Kidney Cancer
  • Lung Cancer
  • Thyroid Cancer
  • Gynecologic Cancer
  • Pancreatic Cancer
  • Stomach Cancer
  • Brain Tumor
  • Colon Cancer
  • Rectal Cancer
  • Head and Neck Cancer
  • Oral Cancer
  • Liver Cancer
  • Skin Cancer
  • Prostate Cancer
  • Testicular Cancer
  • Solid Tumor
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 11 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Brian Henick, MD is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written by subject or guardian
  • Individuals >18 years of age
  • Diagnosis of an irAE clinically suspected to be IL-17 mediated
  • Intent-to-treat or prior treatment with systemic for irAE management
  • Histology-proven primary advanced or solid organ treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll.
  • Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\< 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation.
  • Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test.
  • Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab.

Exclusion criteria

Exclusion Criteria:

  • Estimated \< 40 mg/min
  • Active suicidal ideation or severe depression (as defined by the Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score > 20
  • History of prior suicide attempts
  • PHQ-9 score greater >5 and \< 20 without an established mental health provider who verifies stability in their depression
  • Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV)
  • In the opinion of the investigator, the patient requires additional treatment (other than and brodalumab)
  • Known or to brodalumab, corticosteroids or any components of brodalumab
  • Prior treatment with brodalumab
  • Pregnancy, breastfeeding, or use of a nonreliable method of

    • For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years , with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range).
    • Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method.
    • Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll
  • Chronic or current severe infection requiring IV therapy
  • Evidence of active , C, or tuberculosis.
  • History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated
  • History of or active Crohn's disease.
  • Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first product dose
  • Any concurrent medical condition or (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.
  • Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report
  • Other known active medical conditions, such as:

    • Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D)
    • (AST) and or alanine aminotransferase (ALT) greater than 2 times the or greater than 3 times the upper limit of normal in patients with liver measured on at least two separate occasions
    • Direct greater than or equal to 1.5 mg/dL in patients with or without liver metastases
    • Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \<2000/mm3, \<1500/ mm3, thrombocytopenia ( count) \<50,000/mm3, \< 8.0 g/dL
  • Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE
  • Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit
  • Previous diagnosis of an disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration
  • Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation
  • Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (estimated)

Study arms

  • Experimental
    brodalumab to treat irAEs in patient with solid tumors

    Brodalumab 210 mg subcutaneous injection on weeks 0, 1, 2 followed by administration every 2 weeks until week 24

    Drug: Brodalumab · Radiation: CT scan

Interventions

  • Brodalumab 210 mg subcutaneous injection

    Also known as: SILIQ

  • RadiationCT scan

    CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events

    The number of adverse events of each grade that occur and the number of adverse events attributed to brodalumab, as per the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5).

    Time frame: Up to 36 weeks

  2. Percentage of primary Immune-Related Adverse Event (irAE) severity decreased

    The percentage of patients whose primary irAE severity decreased by \>1 grade per CTCAE criteria from study completion to treatment discontinuation.

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage net decrease in the average steroid dose required for irAE management

    The percentage of patients with a net decrease in the average steroid dose required for irAE management (defined by the ratio of the average steroid dose in prednisone equivalents over the 7 days following enrollment compared to the average dose in the 7 days prior to study completion).

    Time frame: Up to 36 weeks

  2. Proportion of Patients Successfully Tapered Off Steroids

    The proportion of patients who can be tapered completely off of steroids (and remain off for a minimum of 1 week).

    Time frame: Up to 36 weeks

  3. Mean Time to Complete Resolution of irAE Symptoms

    Mean time to complete resolution of irAE clinical manifestation ((as defined as absence of signs/symptoms consistent with the irAE or return to baseline symptoms prior to irAE development)).

    Time frame: Up to 36 weeks

  4. Change in Tumor Burden Assessed by RECIST Criteria at 24 Weeks

    Change in tumor burden as measured by RECIST criteria comparing CT/MRI scan at the time of enrollment to CT/MRI scan at 24 weeks.

    Time frame: 24 weeks

  5. Proportion of Patients with Grade 3 or Higher Infection Events

    The proportion of patients with \> grade 3 infection per CTCAE.

    Time frame: Up to 36 weeks

  6. Cumulative Steroid Exposure over 24 Weeks

    Cumulative steroid exposure (in prednisone equivalents) over 24 weeks

    Time frame: 24 weeks

  7. FACT-G global assessment score

    Change in the quality of life as measured by the Functional Assessment of Cancer Therapy - General (FACT-G) global assessment score. Score range is 0-108. Higher scores indicate a better quality of life, while lower scores suggest worse outcomes.

    Time frame: Baseline and 24 weeks

  8. Progression-free survival (PFS)

    PFS is defined as the duration of time from the start of treatment to the time of progression or death, whichever occurs first, measured in months

    Time frame: Up to 36 weeks

  9. Overall Survival (OS)

    OS is defined as the duration of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive, measured in months.

    Time frame: Up to 36 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2027, 26 months after the start.

Of 373 non-industry phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 77. This study's planned 26 months is below that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 4, 2024
StartActual
Mar 11, 2025
Primary completionEst.
May 2027
CompletionEst.
Nov 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06673329
Lead sponsor
Brian Henick, MD
Responsible party
Brian Henick, MD (Assistant Professor of Medicine, Division of Hematology/Oncology, Columbia University) — Sponsor-investigator
First posted
Nov 4, 2024
Start date
Mar 11, 2025
Primary completion
May 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
May 13, 2026

Study contacts

Research Nurse Navigator
Contact
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
Brian Henick, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brodalumab

Start the discussion